COMP360 Safety & Suicidality Data in TRD | Steve Levine, MD скачать в хорошем качестве

COMP360 Safety & Suicidality Data in TRD | Steve Levine, MD

In this interview, Steve Levine, MD, chief patient officer at Compass Pathways, breaks down key safety findings from the COMP005 and COMP006 trials, including most adverse events resolving within 24 hours, no imbalance in suicidality across treatment arms, and durability of benefit up to 26 weeks after 1 or 2 doses. Levine also discusses how COMP360 compares to existing TRD options and whether, if approved, it could shift the current treatment algorithm. Learn more about this phase 3 data here: https://www.hcplive.com/view/comp360-... Subscribe for more clinician-focused insights on emerging psychiatric therapies. #Psychiatry #TRD #Depression #TreatmentResistantDepression